Similar Search Results

Expected Profits and the Scientific Novelty of Innovation

Dranove, David; Garthwaite, Craig; Hermosilla, Manuel - 2022

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …

Persistent link: https://www.econbiz.de/10013309194

Dynamic mergers effects on R&D investments and drug development across research phases in the pharmaceutical industry

Siebert, Ralph; Tian, Zhili - 2020

Pharmaceutical ﬁrms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop ﬁrms' internal drug development capability. We evaluate the effects of M&As on ﬁrms' post-merger R&D...

Persistent link: https://www.econbiz.de/10012219372

The Role of Assets in Place : Loss of Market Exclusivity and Investment

Higgins, Matthew John; Kronlund, Mathias; Park, Ji Min; … - 2022

We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...

Persistent link: https://www.econbiz.de/10013406834

The Future of Drug Development : The Economics of Pharmacogenomics

Vernon, John A.; Hughen, W. Keener; Vernon, John A. - 2021

This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...

Persistent link: https://www.econbiz.de/10013311658

The Cost of Us Pharmaceutical Price Reductions : A Financial Simulation Model of R&D Decisions

Abbott, Thomas A.; Vernon, John A. - 2021

Previous empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have...

Persistent link: https://www.econbiz.de/10013227913

Private and Social Returns to R&D : Drug Development and Demographics

Benmelech, Efraim; Eberly, Janice; Krieger, Joshua; … - 2022

Investment in intangible capital—in particular, research and development—increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...

Persistent link: https://www.econbiz.de/10014264816

The effect of intellectual property rights on domestic innovation in the pharmaceutical sector

Gamba, Simona - 2016

This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of …. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …

Persistent link: https://www.econbiz.de/10011509446

Pharmaceutical innovation, longevity, and medical expenditure in Greece, 1995 - 2010

Lichtenberg, Frank - 2015

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) - about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

Persistent link: https://www.econbiz.de/10010473542

The contribution of pharmaceutical innovation to longevity growth in Germany and France

Lichtenberg, Frank R. - 2010

I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-2006. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer …

Persistent link: https://www.econbiz.de/10003977959

The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010 : evidence from longitudinal, disease-level data

Lichtenberg, Frank R.; Pettersson, Billie - 2012

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

Persistent link: https://www.econbiz.de/10009571756